Pub. Date : 2021 Jul
PMID : 34304363
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. | Celecoxib | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 2 | Many studies reported that CYP2C9 genetic polymorphism has significant effects on the pharmacokinetics of celecoxib and the occurrence of adverse drug reactions. | Celecoxib | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 3 | The aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model of celecoxib according to CYP2C9 genetic polymorphism for personalized pharmacotherapy. | Celecoxib | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 4 | Based on the conducted pharmacokinetic study and a previous pharmacokinetic study involving subjects with CYP2C9*1/*13 and CYP2C9*3/*3 genotype, PBPK model for celecoxib was developed. | Celecoxib | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 5 | Based on the conducted pharmacokinetic study and a previous pharmacokinetic study involving subjects with CYP2C9*1/*13 and CYP2C9*3/*3 genotype, PBPK model for celecoxib was developed. | Celecoxib | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 6 | As a result, the developed PBPK model of celecoxib successfully described the pharmacokinetics of each CYP2C9 genotype group and its predicted values were within the acceptance criterion. | Celecoxib | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 7 | This study demonstrates the possibility of determining the appropriate dosage of celecoxib for each individual through the PBPK modeling with CYP2C9 genomic information. | Celecoxib | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |